BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 22085556)

  • 1. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing efficacy of mucosal vaccines.
    Gebril A; Alsaadi M; Acevedo R; Mullen AB; Ferro VA
    Expert Rev Vaccines; 2012 Sep; 11(9):1139-55. PubMed ID: 23151169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mucosal immunity and vaccine development].
    Anjuère F; Czerkinsky C
    Med Sci (Paris); 2007 Apr; 23(4):371-8. PubMed ID: 17433226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.
    Anjuère F; Bekri S; Bihl F; Braud VM; Cuburu N; Czerkinsky C; Hervouet C; Luci C
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():117-22. PubMed ID: 22882377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccines: the promise and the challenge.
    Neutra MR; Kozlowski PA
    Nat Rev Immunol; 2006 Feb; 6(2):148-58. PubMed ID: 16491139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel vaccine development strategies for inducing mucosal immunity.
    Fujkuyama Y; Tokuhara D; Kataoka K; Gilbert RS; McGhee JR; Yuki Y; Kiyono H; Fujihashi K
    Expert Rev Vaccines; 2012 Mar; 11(3):367-79. PubMed ID: 22380827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal immunization: a review of strategies and challenges.
    Patel H; Yewale C; Rathi MN; Misra A
    Crit Rev Ther Drug Carrier Syst; 2014; 31(4):273-303. PubMed ID: 25072196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal responses to parenteral and mucosal vaccines.
    Kaul D; Ogra PL
    Dev Biol Stand; 1998; 95():141-6. PubMed ID: 9855424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jump-starting the immune system: prime-boosting comes of age.
    Woodland DL
    Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of CpG DNA as a mucosal vaccine adjuvant.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting mucosal surfaces for the development of mucosal vaccines.
    Meeusen EN
    Vaccine; 2011 Nov; 29(47):8506-11. PubMed ID: 21945494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology solutions for mucosal immunization.
    Chadwick S; Kriegel C; Amiji M
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):394-407. PubMed ID: 19931581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal vaccination--an old but still vital strategy.
    Długońska H; Grzybowski M
    Ann Parasitol; 2012; 58(1):1-8. PubMed ID: 23094329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.